Onkure Therapeutics, Inc. (OKUR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Onkure Therapeutics, Inc. on November 6, 2025. The filing discloses the entry into a material definitive agreement to establish an "at-the-market" equity offering program.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new sales agreement.
Material Changes and Agreements
- Sales Agreement: On November 6, 2025, the Company entered into a Sales Agreement with Leerink Partners LLC to sell shares of its Class A common stock.
- Program Structure: The agreement establishes an "at-the-market" offering program where Leerink Partners acts as the sales agent.
- Compensation: Leerink Partners is entitled to a commission of up to 3.0% of the gross proceeds from sales of Placement Shares.
- Termination: Either party may terminate the agreement with 10 days' prior notice, or immediately under certain circumstances such as a material adverse change.
- Registration: Shares will be sold pursuant to a shelf registration statement on Form S-3, with a prospectus supplement to be filed on November 6, 2025. No sales may occur until the Registration Statement becomes effective.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard terms of the Sales Agreement. The Company retains the sole discretion to set sales parameters, including price floors and daily volume limits, and has no obligation to sell any shares under the agreement.
Key Facts for Investor Verification
- Verify the effectiveness date of the Form S-3 Registration Statement and the accompanying prospectus supplement.
- Monitor future filings for the actual volume and pricing of shares sold under the new program.
- Review the Company's most recent 10-K or 10-Q for current cash position and liquidity needs, as this 8-K does not disclose financial status.
- Confirm the total number of shares authorized for sale under the shelf registration, as the 8-K does not specify a maximum cap for this specific agreement.